EPS for Grifols, S.A. (GRFS) Expected At $0.31

September 30, 2018 - By Lisa Delgado

Grifols, S.A. (NASDAQ:GRFS) Logo

Analysts expect Grifols, S.A. (NASDAQ:GRFS) to report $0.31 EPS on November, 1.They anticipate $0.02 EPS change or 6.90 % from last quarter’s $0.29 EPS. GRFS’s profit would be $252.21 million giving it 17.23 P/E if the $0.31 EPS is correct. After having $0.34 EPS previously, Grifols, S.A.’s analysts see -8.82 % EPS growth. The stock increased 0.38% or $0.08 during the last trading session, reaching $21.37. About 1.69 million shares traded or 70.93% up from the average. Grifols, S.A. (NASDAQ:GRFS) has declined 3.12% since September 30, 2017 and is downtrending. It has underperformed by 18.74% the S&P500.

Grifols, S.A., a specialty pharmaceutical company, develops, makes, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company has market cap of $17.39 billion. The firm specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. It has a 35.68 P/E ratio. It operates through four divisions: Bioscience, Diagnostic, Hospital, and Raw Materials and Others.

More news for Grifols, S.A. (NASDAQ:GRFS) were recently published by: Globenewswire.com, which released: “Recent Analysis Shows Green Plains Partners LP, Companhia Paranaense de Energia (COPEL), China Yuchai …” on September 26, 2018. Bizjournals.com‘s article titled: “Grifols: Just-approved medicine will only be manufactured in Clayton” and published on September 07, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: